In fiscal 2023, the equity of the Merck Group rose by 2.9 % to € 26,754 million (December 31, 2022: € 26,005 million). Profit after tax (€ 2,834 million) contributed to this development. By contrast, a negative currency translation difference (€ 1,003 million) and...
Group-wide research and development costs rose by 3.9% to € 2,521 million in 2022 (2021: € 2,426 million) and led to a research spending ratio (research and development costs as a percentage of net sales) of 11.3% (2021: 12.3%). Accounting for a 70% (2021: 73%)...
In cardiovascular disease, Merck announced positive topline results from the Phase 3 ZENITH study, evaluating WINREVAIR in adults with pulmonary arterial hypertension (PAH) with World Health Organization (WHO) Group 1 functional class (FC) III or IV at high risk of mortality. Based on the posit...
Annual Report 2024 On March 6, 2025, we will publish the results of the fourth quarter and full-year 2024 at 7 a.m. CET. Sparking Discovery, Elevating Humanity As a vibrant science and technology company, we are sparking discovery and elevating humanity. About us Life Science Healthcare ...
Annual Report 2024 On March 6, 2025, we will publish the results of the fourth quarter and full-year 2024 at 7 a.m. CET. Sparking Discovery, Elevating Humanity As a vibrant science and technology company, we are sparking discovery and elevating humanity. About us Life Science Healthcare ...
Annual Report 2024 Merck returned to profitable growth in 2024 and delivered on its guidance for the year. Sparking Discovery, Elevating Humanity As a vibrant science and technology company, we are sparking discovery and elevating humanity. About us Life Science Healthcare Electronics Business Ethics...
Annual Report 2024 Merck returned to profitable growth in 2024 and delivered on its guidance for the year. Sparking Discovery, Elevating Humanity As a vibrant science and technology company, we are sparking discovery and elevating humanity. About us Life Science Healthcare Electronics Business Ethics...
Annual Report 2024 On March 6, 2025, we will publish the results of the fourth quarter and full-year 2024 at 7 a.m. CET. Sparking Discovery, Elevating Humanity As a vibrant science and technology company, we are sparking discovery and elevating humanity. About us Life Science Healthcare ...
Annual Report 2024 On March 6, 2025, we will publish the results of the fourth quarter and full-year 2024 at 7 a.m. CET. Sparking Discovery, Elevating Humanity As a vibrant science and technology company, we are sparking discovery and elevating humanity. About us Life Science Healthcare ...
If approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor therapy for pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to be approved in Europe, offering a new treatment option for certain adults with this rare, progressive ...